장기간 또는 반복 노출되면 장기(또는, 영향을 받은 알려진 모든 장기를 명시)에 손상을 일으킬 수 있음
특정 표적장기 독성 - 반복 노출
구분 2
경고
P260, P314, P501
예방조치문구:
P262
눈, 피부, 의복에 묻지 않도록 하시오.
P280
보호장갑/보호의/보안경/안면보호구를 착용하시오.
P312
불편함을 느끼면 의료기관(의사)의 진찰을 받으시오.
NFPA 704
0
3
0
Selumetinib C화학적 특성, 용도, 생산
개요
Selumetinib (AZD6244; ARRY-142886) is an oral MEK inhibitor. In a randomized trial, NSCLC patients with wild-type KRAS were randomized to erlotinib
alone or combination therapy with selumetinib, while mutant KRAS patients were
randomized to selumetinib alone or combination therapy. The primary end points
were PFS for the KRAS wild-type cohort and objective response rate (ORR) for the
KRAS mutant cohort. Results were not impressive, with no PFS difference in the
KRAS wild-type arm (2.4 vs. 2.1?months) and no ORR difference in the KRASmutated subgroup (0% vs. 10%). A planned trial of selumetinib in combination
with the anti-PD-L1 antibody durvalumab has since been suspended (NCT03004105).
정의
ChEBI: A member of the class of benzimidazoles that is 1-methyl-1H-benzimidazole which is substituted at positions 4, 5, and 6 by fluorine, (4-bromo-2-chlorophenyl)amino, and N-(2-hydroxyethoxy)aminocarbonyl groups, respectiv
ly. It is a MEK1 and MEK2 inhibitor.